Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Crohn Disease (CD) Colitis Colitis, Ulcerative Colonic Diseases Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Ulcerative Colitis (UC)

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Imelda General Hospital

Bonheiden, 2820, Belgium

Location status: Recruiting

Location contact

Peter Bossuyt, MD PhD

CONTACT

[email protected]

+3215505691

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

≥18 years
Patient with confirmed diagnosis of IBD
Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
willing to provide informed consent

Exclusion criteria

Patient with IBD unspecified
Patient with ileo- or colostomy
Patient with total colectomy
Women that are pregnant

Treatment and study plan

Leucine-rich α2-glycoprotein

Diagnostic Test

Leucine-rich α2-glycoprotein measurement

Primary outcomes

Correlation between LRG serum level and endoscopic disease activity in CD and UC

Time frame: Day 1

Correlation between LRG serum level and endoscopic disease activity in CD and UC

Study contacts

Contact information is provided by the study sponsor or research team.

Peter Bossuyt

CONTACT

[email protected]

MD PhD

Sponsors and collaborators

Lead sponsor

Imelda GI Clinical Research Center

Other

Registry information

Official study title

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial.

Acronym: LEADER

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jun 2, 2026
Registry last updated: Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting